Literature DB >> 30230967

Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.

Jingjing Cai1,2,3,4, Meng Xu1,2,3, Xiaojing Zhang1,2,3, Hongliang Li1,2,3.   

Abstract

The physiological significance of innate immune signaling lies primarily in its role in host defense against invading pathogens. It is becoming increasingly clear that innate immune signaling also modulates the development of metabolic diseases, especially nonalcoholic fatty liver disease and cardiovascular diseases, which are characterized by chronic, low-grade inflammation due to a disarrangement of innate immune signaling. Notably, recent studies indicate that in addition to regulating canonical innate immune-mediated inflammatory responses (or immune-dependent signaling-induced responses), molecules of the innate immune system regulate pathophysiological responses in multiple organs during metabolic disturbances (termed immune-independent signaling-induced responses), including the disruption of metabolic homeostasis, tissue repair, and cell survival. In addition, emerging evidence from the study of immunometabolism indicates that the systemic metabolic status may have profound effects on cellular immune function and phenotypes through the alteration of cell-intrinsic metabolism. We summarize how the innate immune system interacts with metabolic disturbances to trigger immune-dependent and immune-independent pathogenesis in the context of nonalcoholic fatty liver disease, as representative of metabolic diseases, and cardiovascular diseases.

Entities:  

Keywords:  CVD; NAFLD; cardiovascular disease; immunometabolism; innate immunity; metabolic disease; nonalcoholic fatty liver disease

Mesh:

Year:  2018        PMID: 30230967     DOI: 10.1146/annurev-pathmechdis-012418-013003

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  17 in total

Review 1.  Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.

Authors:  Ming-Ming Chen; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-02

2.  Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation.

Authors:  Yanan Chu; Fangcong Yu; Yakui Wu; Jinxiu Yang; Jiaran Shi; Tianxin Ye; Deheng Han; Xingxiang Wang
Journal:  BMC Med Genomics       Date:  2022-07-05       Impact factor: 3.622

Review 3.  Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk.

Authors:  Agostino Di Ciaula; Jacek Baj; Gabriella Garruti; Giuseppe Celano; Maria De Angelis; Helen H Wang; Domenica Maria Di Palo; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  J Clin Med       Date:  2020-08-14       Impact factor: 4.241

4.  Group 3 Innate Lymphoid Cells Protect Steatohepatitis From High-Fat Diet Induced Toxicity.

Authors:  Masahide Hamaguchi; Takuro Okamura; Takuya Fukuda; Kensuke Nishida; Yuta Yoshimura; Yoshitaka Hashimoto; Emi Ushigome; Naoko Nakanishi; Saori Majima; Mai Asano; Masahiro Yamazaki; Hiroshi Takakuwa; Masakazu Kita; Michiaki Fukui
Journal:  Front Immunol       Date:  2021-03-15       Impact factor: 7.561

Review 5.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 6.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

7.  Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.

Authors:  Chongshu Jian; Jiajun Fu; Xu Cheng; Li-Jun Shen; Yan-Xiao Ji; Xiaoming Wang; Shan Pan; Han Tian; Song Tian; Rufang Liao; Kehan Song; Hai-Ping Wang; Xin Zhang; Yibin Wang; Zan Huang; Zhi-Gang She; Xiao-Jing Zhang; Lihua Zhu; Hongliang Li
Journal:  Cell Metab       Date:  2020-05-05       Impact factor: 31.373

Review 8.  COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.

Authors:  Piero Portincasa; Marcin Krawczyk; Wiktor Smyk; Frank Lammert; Agostino Di Ciaula
Journal:  Eur J Clin Invest       Date:  2020-08-26       Impact factor: 5.722

9.  Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.

Authors:  Junjian Hu; Hongwu Wang; Xitang Li; Yonggang Liu; Yuqiang Mi; Hongyan Kong; Dong Xi; Weiming Yan; Xiaoping Luo; Qin Ning; Xiaojing Wang
Journal:  Theranostics       Date:  2020-08-01       Impact factor: 11.556

Review 10.  Research progress on Toll-like receptor signal transduction and its roles in antimicrobial immune responses.

Authors:  Pengpeng Xia; Yunping Wu; Siqi Lian; Li Yan; Xia Meng; Qiangde Duan; Guoqiang Zhu
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-28       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.